Aim We evaluated gastrointestinal (GI) adverse events (AEs) with once‐weekly semaglutide
2.4 mg in adults with overweight or obesity and their contribution to weight loss (WL) …

Background Obesity is a global health challenge with few pharmacologic options. Whether
adults with obesity can achieve weight loss with once-weekly semaglutide at a dose of 2.4 …

Aims To evaluate the efficacy and safety of oral semaglutide versus comparators by patient
characteristic subgroups in patients with type 2 diabetes. Materials and Methods Change …

Aim Glucagon‐like peptide‐1 receptor agonists improve glycaemic control: some are now
available as oral and subcutaneous formulations, and some have indications for reducing …

Aim To investigate the effects of once‐weekly subcutaneous (sc) semaglutide 2.4 mg on
gastric emptying, appetite, and energy intake in adults with obesity. Materials and Methods A …

Aims To assess the effect of baseline body mass index (BMI) and the occurrence of nausea
and/or vomiting on weight loss induced by semalgutide, a once‐weekly glucagon‐like …

Background We assessed the efficacy and safety of the oral glucagon-like peptide-1
analogue, semaglutide 50 mg, taken once per day versus placebo for the treatment of …

Introduction Gastrointestinal (GI) adverse events (AEs) are the most common AEs with
glucagon-like peptide-1 receptor agonists (GLP-1RAs). Weight loss (WL) is slightly greater …

Aim To explore the safety and efficacy of subcutaneous semaglutide 2.4 mg, administered
once a week in non‐diabetic overweight or obese individuals. Methods A thorough search …

Aims To investigate whether the pharmacokinetic characteristics of semaglutide were
altered in people with hepatic impairment, assessed using Child–Pugh criteria, vs those with …